MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
CareDx, Inc Retained Earnings 2011-2025 | CDNA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings CareDx, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -678 M | -460 M | -383 M | -353 M | -334 M | -312 M | -268 M | -213 M | -173 M | -159 M | -160 M | -157 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -157 M | -678 M | -304 M |
Quarterly Retained Earnings CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -719 M | -695 M | -637 M | -626 M | -704 M | -697 M | -695 M | -678 M | -534 M | -510 M | -485 M | -460 M | -441 M | - | -403 M | -383 M | -367 M | -355 M | -353 M | -353 M | -353 M | -353 M | -353 M | -334 M | -334 M | -334 M | -334 M | -312 M | -312 M | -312 M | -312 M | -268 M | -268 M | -268 M | -268 M | -213 M | -213 M | -213 M | -213 M | -173 M | -173 M | -173 M | -173 M | -159 M | -159 M | -159 M | -159 M | -160 M | -160 M | -160 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -159 M | -719 M | -357 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 19.33 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 20.97 | -1.38 % | $ 226 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 0.23 | -4.4 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 39.53 | -1.4 % | $ 1.1 B | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.52 | - | $ 1.93 M | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 10.17 | 1.29 % | $ 289 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
1.02 B | $ 67.51 | 0.13 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
44.2 B | $ 230.0 | -0.45 % | $ 168 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 101.56 | 0.02 % | $ 18.8 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 26.78 | -0.85 % | $ 810 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 101.9 | -0.7 % | $ 4.02 B | USA |
 |
Anixa Biosciences
ANIX
|
-241 M | $ 3.21 | -6.25 % | $ 102 K | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
6.06 B | $ 226.52 | 0.26 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-2.58 B | $ 103.35 | 0.94 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
-757 M | $ 6.44 | -1.68 % | $ 583 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 135.12 | -0.15 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
1.81 B | $ 203.88 | - | $ 10.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-103 M | $ 4.94 | -3.14 % | $ 2.65 M | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 7.12 | -0.35 % | $ 1.54 B | USA |
 |
National Research Corporation
NRC
|
-30.5 M | $ 18.74 | 0.46 % | $ 460 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 176.16 | 0.15 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 6.76 | -0.88 % | $ 877 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 254.32 | 0.02 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 182.75 | -0.51 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
5.33 B | $ 688.22 | 0.01 % | $ 56.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
-1.84 B | $ 1.77 | -5.85 % | $ 449 M | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 66.73 | 0.07 % | $ 4.62 B | USA |
 |
Mettler-Toledo International
MTD
|
8.37 B | $ 1 419.64 | 0.11 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
348 M | $ 138.31 | 0.03 % | $ 42 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.7 | 1.9 % | $ 6.2 M | USA |
 |
Bioventus
BVS
|
-322 M | $ 7.4 | 0.27 % | $ 464 M | USA |
 |
NeoGenomics
NEO
|
-326 M | $ 12.33 | 0.2 % | $ 1.56 B | USA |